Discover a number of perspectives and views on the PRI, the Microbiota & Human Health Industry and the people and companies driving this field forward.

Nina Vinot, Regional Sales Manager for Western Europe, Probiotical, explains how the PRI supports its members in marketing their products.

Peter Cartwright, R&D Director, Protexin, talks about how the PRI has adopted a pioneering approach to registering LBPs as medicines.

Richard Ellis, Business Developer at the PRI, explains how the PRI Partnering Platform is providing access to the human microbiome supply chain.

Dr. Muriel Cazaubiel, CEO of Biofortis, explains why an established CRO has become a member of the PRI.

Martha Carlin, CEO of TheBioCollective, talks about why a US-based biotech decided to become a member of the PRI.

Dr. Marco Pané, R&D Manager at Probiotical, discusses how the PRI drives through new initiatives with their innovative Task Groups.

Dr. Etienne Nouguez of CNRS and Sciences Po – Paris, has a different perspective for becoming a PRI member.

Dr. Pierre-Yves Mousset, CEO of Indigo Therapeutics and Board member of the PRI, talks about why the PRI is interesting for start-ups.

Dr. Massimo Marzorati, Co-founder and Business Development Director of Prodigest, discusses how the PRI has become a truly European Association.

Dr. Magali Cordaillat-Simmons, Regulatory and Scientific Director of the PRI, details how the organisation has aided its members with the speed to market of their Microbiotic Medicinal Products.

Dr. Jean-Pol Warzée, Technical Director of Vésale Pharma and Board member of the PRI, describes the PRI’s successful conference promoted and organised by I² Media.

Dr. Jaimé Lopez of Ferring Pharmaceuticals argues why big pharma should be involved with the PRI.

Pr. Bruno Pot, PRI President, discusses how the PRI is building the bridge between academia and the industry.

Stanislas Desjonquères, CEO of Biose and member of the PRI, is taking Microbiotic Medicinal Products to market!